EDAP TMS Announces Strong Revenue Performance For the Nine Months Ending September 30, 2004
14 Octubre 2004 - 8:12AM
PR Newswire (US)
EDAP TMS Announces Strong Revenue Performance For the Nine Months
Ending September 30, 2004 - Management to Host a Conference Call to
Discuss Its 2004 Third Quarter Results on October 28, 2004 -
VAULX-EN-VELIN, France, Oct. 14 /PRNewswire-FirstCall/ -- EDAP TMS
S.A. (NASDAQ:EDAP), a global leader in the development, marketing
and distribution of a portfolio of minimally-invasive medical
devices for the treatment of urological diseases, today announced
strong revenue performance for the first nine months of 2004. As of
September 30, 2004, EDAP TMS recorded, at fixed exchange rate, a
21% increase in its total revenues compared to the same period of
2003. Total revenue amounted approximately EUR 16,1 million for the
first nine months of 2004 versus EUR 13,5 million for the same
period of last year. In comparison with the first nine months of
2003, it is to be highlighted: -- an exceptional 158% increase in
Ablatherm sales, -- a progression of 123% in Ablatherm treatments
sold per procedure, on a mobile or leasing basis, -- an 8% increase
in lithotriptors sales on a very mature market. EDAP, the HIFU
Division, recorded an excellent revenue for the period ending
September 30, 2004 with a 106% increase in its total revenue
directly linked to its HIFU activity compared with the same period
of 2003. This major progression confirms the growing recognition of
Ablatherm, using HIFU technology to treat localized prostate
cancer. TMS, the UDS & lithotripsy Division, progresses on a
mature market. This growth validates EDAP TMS aggressive strategy
to gain market shares. Hugues de Bantel, Chief Executive Officer of
EDAP TMS, commented: "The performance of EDAP TMS as of September
30, 2004 confirms our double digit growth objective for the total
year 2004. We look forward to commenting and discussing our third
quarter and nine months 2004 financial results with our
shareholders and the investment community during the conference
call to be held on Thursday October 28, 2004, 12:00 noon New York
Time, following the Company's post-market press release on
Wednesday October 27, 2004." The conference call will be broadcast
live over the internet on our website at http://www.edap-tms.com/,
in our "investor information" section. EDAP TMS S.A. is the global
leader in the development, production, marketing and distribution
of a portfolio of minimally invasive medical devices primarily for
the treatment of urological diseases. The Company currently
develops and markets devices for the minimally invasive treatment
of localized prostate cancer, using High Intensity Focused
Ultrasound (HIFU), through its HIFU Division; it is also developing
this technology for the treatment of certain other types of tumors.
EDAP TMS S.A. also produces and commercializes medical equipment
for treatment of urinary tract stones using Extra-corporeal
Shockwave Lithotripsy (ESWL), via its Urology Devices and Services
(UDS) Division. In addition, the Company markets devices for the
non- surgical treatment of benign Prostate Hyperplasia (BPH) using
Microwave Thermotherapy (TUMT). For more information on the
Company, contact our Investor Relations Dept by phone at +33 (0)4
78 26 40 46 or please see the Company's web site at:
http://www.edap-tms.com/. This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. CONTACT: Hugues de Bantel /
Blandine Confort +33 4 78 26 40 46 DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel or Blandine Confort, both of EDAP TMS
S.A., +33-4-78-26-40-46 Web site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024